The future for $NRTI just improved GREATLY!
The more I review the actions being taken by the FDA the better I feel about NRTI's CBD Initiative. When you take an in depth look into their CBD Initiative and who they have on their Scientific & Medical Advisory Board, they have aligned themselves perfectly with what the FDA is asking for. What does NRTI have that none of the other CBD companies have? Near the end of this message is a list of what NRTI has incorporated into their CBD Initiative and though some of the other CBD companies may have some of these built into their approach, they do not have the whole package that NRTI has that is most aligned to what the FDA is asking for.
This will matter greatly in the longer term, as the FDA has made it clear that they will only work with those companies who have taken the proper procedures in creating a safe product that is supported by reliable research. We couldn't have asked for a better situation than what the FDA has just created with their new CBD policy that will make it very difficult for many of these other CBD companies to survive. This opens the door for NRTI to begin a conversation with the FDA about their GOLD STANDARD APPROACH, which is exactly what they are looking for.
As I said many times before, NRTI can help set the new standard for the entire medical marijuana industry and in particular the CBD side. It also provides NRTI the additional time to get their ducks all in a row, as it is more unlikely now that any other CBD company will be able to take their CBD products to the retail trade very soon. The FDA has just thrown up a huge barrier that will have to overcome before they are able to market their CBD products to the retail mainstream.
Previously I had some big concerns that another CBD company was going to beat NRTI to the punch to become the first company to take a CBD product to the retail mainstream, but after the FDA's actions, that is very doubtful in the near term now. It is going to take some time for the FDA to review what these CBD companies will submit to get their CBD products approved for retail and they will have to make some considerable changes before they can even approach the FDA for any kind of approval.
I have also said many times in the past that NRTI has taken the right approach, even though it required a considerable amount of resources to reach this point to create their first CBD product for the retail trade. They invested a lot of time and money into getting this right and per the recent actions of the FDA, it will be well worth it in the end. Of course they will now need to begin working with the FDA as soon as possible to keep the ball rolling in an effort to get Nulief launched into the retail mainstream in the near future.
NRTI took a big misstep with their Nulief launch event that was no way ready for this big launch. That should have been saved until they were ready to roll it out to retail. That misstep created a big setback for the company and us shareholders, as the market was expecting so much more behind their launch event than distribution to one dispensary. Kras told me in an email that there is a Nulief plan that I obviously do not want to comprehend, along with some additional childlike comments to attack me, but the fact is we are all unaware of those plans due to the company keeping it to themselves. There would not be a better time than the present to let shareholders what they have in store for Nulief and their CBD Initiative. It is the least they can do after causing this mess with their premature Nulief launch event that left everyone disappointed and confused. It may be the bottom of the ninth inning with two outs and down by 3 runs, but NRTI can hit a grand slam to win the game by updating the market with their CBD Initiative plans and their go-to-market strategy for Nulief.
With the recent FDA decision that has many CBD companies scrambling, NRTI could quickly rise to the top with an announcement about how their BEST-IN-CLASS QUALITY CBD PRODUCTS align perfectly with what the FDA has laid out for the CBD industry, along with their cooperation to work with the FDA to help instill new standards for the CBD industry with their GOLD STANDARD APPROACH that includes the following:
* Proper Research and data from respectable sources within the medical marijuana industry who have worked and studied in this field for a very long time to support the product creation.
* Best-In-Class ingredients that are pure and free of any contaminates
* Proper CBD extraction techniques that are supported by proper research data
* NSF certified manufacturing facility and process to ensure a consistent CBD product that is produced as labeled and free of contaminants that is stored and shipped per the NSF standards.
* Proper labeling and marketing that is void of any claims which have not been proven through the approved research and clinical testing required by the FDA.
This is what the FDA is asking for and NRTI has taken all the right steps to meet and exceed their standards for the CBD industry. There could very well be a few issues that need further adherence by the FDA, but given NRTI's approach, they are light years ahead of the competition when it comes to aligning themselves with what the FDA is now requiring for CBD products before they will be allowed for sale in the US.
The legal precedent that was set in federal court in regards to hemp based CBD products still makes it perfectly legal to sell and distribute hemp based CBD products that obtained their hemp from outside the US. However, if the FDA finds such products harmful and unsafe, I think they can take action to suspend such actions. That is why it stated the following in the news about the FDA findings:
When considering all that has happened with this recent development by the FDA and the approach that NRTI has taken with their CBD Initiative and with their newly created CBD product to treat pain, Nulief, there is much to be optomistic about in the longer term. They can't afford to make any more missteps like they did with the Nulief launch event and they have to quickly approach the FDA to begin the process of creating the new standard while getting additional approval from the FDA to become the first company to take CBD to the retail mainstream and the first and possibly the only company to have the FDA approve their CBD products. We will need to monitor the situation closely as things progress from here. NRTI could also help themselves greatly with a much needed update on their CBD initiative and Nulief that shares their go-to-market strategy, as well as their plans to work closely with the FDA. That would go a long way in restoring investor confidence as we await further developments. Cheers!
The more I review the actions being taken by the FDA the better I feel about NRTI's CBD Initiative. When you take an in depth look into their CBD Initiative and who they have on their Scientific & Medical Advisory Board, they have aligned themselves perfectly with what the FDA is asking for. What does NRTI have that none of the other CBD companies have? Near the end of this message is a list of what NRTI has incorporated into their CBD Initiative and though some of the other CBD companies may have some of these built into their approach, they do not have the whole package that NRTI has that is most aligned to what the FDA is asking for.
This will matter greatly in the longer term, as the FDA has made it clear that they will only work with those companies who have taken the proper procedures in creating a safe product that is supported by reliable research. We couldn't have asked for a better situation than what the FDA has just created with their new CBD policy that will make it very difficult for many of these other CBD companies to survive. This opens the door for NRTI to begin a conversation with the FDA about their GOLD STANDARD APPROACH, which is exactly what they are looking for.
As I said many times before, NRTI can help set the new standard for the entire medical marijuana industry and in particular the CBD side. It also provides NRTI the additional time to get their ducks all in a row, as it is more unlikely now that any other CBD company will be able to take their CBD products to the retail trade very soon. The FDA has just thrown up a huge barrier that will have to overcome before they are able to market their CBD products to the retail mainstream.
Previously I had some big concerns that another CBD company was going to beat NRTI to the punch to become the first company to take a CBD product to the retail mainstream, but after the FDA's actions, that is very doubtful in the near term now. It is going to take some time for the FDA to review what these CBD companies will submit to get their CBD products approved for retail and they will have to make some considerable changes before they can even approach the FDA for any kind of approval.
I have also said many times in the past that NRTI has taken the right approach, even though it required a considerable amount of resources to reach this point to create their first CBD product for the retail trade. They invested a lot of time and money into getting this right and per the recent actions of the FDA, it will be well worth it in the end. Of course they will now need to begin working with the FDA as soon as possible to keep the ball rolling in an effort to get Nulief launched into the retail mainstream in the near future.
NRTI took a big misstep with their Nulief launch event that was no way ready for this big launch. That should have been saved until they were ready to roll it out to retail. That misstep created a big setback for the company and us shareholders, as the market was expecting so much more behind their launch event than distribution to one dispensary. Kras told me in an email that there is a Nulief plan that I obviously do not want to comprehend, along with some additional childlike comments to attack me, but the fact is we are all unaware of those plans due to the company keeping it to themselves. There would not be a better time than the present to let shareholders what they have in store for Nulief and their CBD Initiative. It is the least they can do after causing this mess with their premature Nulief launch event that left everyone disappointed and confused. It may be the bottom of the ninth inning with two outs and down by 3 runs, but NRTI can hit a grand slam to win the game by updating the market with their CBD Initiative plans and their go-to-market strategy for Nulief.
With the recent FDA decision that has many CBD companies scrambling, NRTI could quickly rise to the top with an announcement about how their BEST-IN-CLASS QUALITY CBD PRODUCTS align perfectly with what the FDA has laid out for the CBD industry, along with their cooperation to work with the FDA to help instill new standards for the CBD industry with their GOLD STANDARD APPROACH that includes the following:
* Proper Research and data from respectable sources within the medical marijuana industry who have worked and studied in this field for a very long time to support the product creation.
* Best-In-Class ingredients that are pure and free of any contaminates
* Proper CBD extraction techniques that are supported by proper research data
* NSF certified manufacturing facility and process to ensure a consistent CBD product that is produced as labeled and free of contaminants that is stored and shipped per the NSF standards.
* Proper labeling and marketing that is void of any claims which have not been proven through the approved research and clinical testing required by the FDA.
This is what the FDA is asking for and NRTI has taken all the right steps to meet and exceed their standards for the CBD industry. There could very well be a few issues that need further adherence by the FDA, but given NRTI's approach, they are light years ahead of the competition when it comes to aligning themselves with what the FDA is now requiring for CBD products before they will be allowed for sale in the US.
The legal precedent that was set in federal court in regards to hemp based CBD products still makes it perfectly legal to sell and distribute hemp based CBD products that obtained their hemp from outside the US. However, if the FDA finds such products harmful and unsafe, I think they can take action to suspend such actions. That is why it stated the following in the news about the FDA findings:
Quote:The FDA “considers many factors” in such decisions, including input from other federal agencies and state officials, and whether such products constitute a threat to public health.
The lack of scientific research and evidence into the medicinal and dietary benefits of marijuana-based products has long been a stumbling block for cannabis companies, including those that specialize in hemp-based CBD products.
The FDA acknowledged this point, and wrote that it will continue to work with companies that are “interested in appropriately bringing safe, effective, and quality products to market, including scientifically-based research concerning the medicinal uses of marijuana.”
When considering all that has happened with this recent development by the FDA and the approach that NRTI has taken with their CBD Initiative and with their newly created CBD product to treat pain, Nulief, there is much to be optomistic about in the longer term. They can't afford to make any more missteps like they did with the Nulief launch event and they have to quickly approach the FDA to begin the process of creating the new standard while getting additional approval from the FDA to become the first company to take CBD to the retail mainstream and the first and possibly the only company to have the FDA approve their CBD products. We will need to monitor the situation closely as things progress from here. NRTI could also help themselves greatly with a much needed update on their CBD initiative and Nulief that shares their go-to-market strategy, as well as their plans to work closely with the FDA. That would go a long way in restoring investor confidence as we await further developments. Cheers!
